Login to Your Account

Clinic Roundup

Tuesday, November 13, 2012
• CellAct Pharma GmbH, of Dortmund, Germany, said its topoisomerase inhibitor CAP7. 1 showed promising safety and tolerability in heavily pretreated solid tumors.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription